sierra health and life GERD/Upper GI Policy Update | OpenPayer
Modifiedsierra health and lifePolicy 2026T0322LL
Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases
Covers medical necessity and investigational determinations for minimally invasive and endoscopic procedures to treat GERD, achalasia, diffuse esophageal spasm, and gastroparesis; applies to evaluation and coverage of specific procedures and devices.
Policy Summary
Payersierra health and life
PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases
Policy CodePolicy 2026T0322LL
Change TypeMaterial revisions to gastroparesis and pyloroplasty coveragecode additions
Effective DateFeb 1, 2026
Next Review Date
Key ActionObtain prior authorization documenting medically refractory gastroparesis and prior therapy failure before scheduling GES or surgical pyloroplasty.
Added language to indicate gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.
Added language to indicate surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic-intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.
Removed language indicating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing achalasia.
Added CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 to applicable codes.
Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.
Updated definition of 'Gastroparesis'.
Added language clarifying that benefit coverage is determined by the member specific benefit plan document and that medical records may be required to assess clinical criteria for coverage.
GES
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
GES proven
POEMPOEM proven for achalasia
Not coveredG-POEM status
12+Codes listed
7CPT codes added
Coverage Determinations and Medical Necessity Criteria
GES and Surgical Pyloroplasty - Medically Necessary Indications
Covered when ALL of the following are met:
GES or pyloroplasty criteria: Gastric electrical stimulation (GES) therapy or surgical pyloroplasty (open or laparoscopic) is medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.failure of other therapies (medically refractory)
Refer to FDA HDE labeling for GES and document objective delayed gastric emptying testing (e.g., scintigraphy) and baseline symptom severity.
POEM - Medically Necessary and Not Medically Necessary Uses
Covered when ALL of the following are met for achalasia/diffuse esophageal spasm; not covered for other indications:
POEM for Achalasia or Diffuse Esophageal Spasm: Per oral endoscopic myotomy (POEM) is medically necessary for individuals with achalasia or diffuse esophageal spasm.diagnosis confirmed by appropriate testing (e.g., high-resolution manometry) and candidate selection per specialty standards
POEM requires advanced endoscopic expertise; evidence includes randomized trials showing noninferiority to LHM for achalasia (Werner et al.).
POEM for other indications: POEM is unproven and not medically necessary for indications other than achalasia or diffuse esophageal spasm (for example, Zenker's diverticulum).N/A
Insufficient evidence of efficacy for other indications.
Endoscopic and Implantable Therapies for GERD - Not Medically Necessary
The following are unproven and not medically necessary due to insufficient evidence of efficacy:
Endoscopic therapies and implants for GERD: Endoscopic therapies (including endoscopic plication/suturing, endoluminal fundoplication/TIF, EsophyX, GERDx), injection or implantation techniques (e.g., Plexiglas, Durasphere), and the LINX Reflux Management System are considered unproven and not medically necessary for treating GERD due to insufficient or low-quality evidence for routine coverage.insufficient evidence of efficacy or lack of long-term safety data
Endoluminal therapy with GERDx is investigational and not FDA approved.
G-POEM - Not Medically Necessary
G-POEM for Gastroparesis: Gastric per oral endoscopic myotomy (G-POEM) is unproven and not medically necessary for the treatment of gastroparesis.insufficient evidence
Available evidence is very low to low quality with heterogeneous success definitions and limited long-term data; comparative RCTs are lacking.
Coverage considerations
Consider coverage when clinical criteria and evidence-based recommendations are met:
GES for refractory gastroparesis: Patient has medically refractory diabetic or idiopathic gastroparesis with persistent symptoms despite standard therapies (documented failure of medical/conservative treatment); GES use aligns with HUD/FDA labeling and specialty guidance (ACG/AGA conditional statements).failed standard therapies; not taking opioids when guidance requires
Document baseline symptom severity and objective delayed gastric emptying testing; evidence includes mixed randomized and open-label studies.
Surgical pyloroplasty vs GES: Consider surgical pyloroplasty (laparoscopic or open) for refractory gastroparesis when appropriate; systematic reviews report pyloroplasty achieves symptomatic and gastric emptying improvements and may be preferred surgical option in many cases.case-specific
Document prior therapy failure and rationale for pyloroplasty versus neurostimulator.
Summary: Z-POEM, G-POEM, and Stretta coverage considerations
Summary coverage stance based on available evidence in this section
Z-POEM has limited evidence from mainly retrospective observational studies and meta-analyses showing comparable short-term symptom resolution to flexible endoscopic septotomy but lacks sufficient long-term comparative data and is at high risk of bias.evidence quality low; limited follow-up
Further high-quality prospective comparative studies with long-term follow-up are needed.
G-POEM demonstrates symptomatic improvement in observational series and some meta-analyses with pooled clinical success in many cohorts, but overall evidence quality is very low to low with heterogeneous outcome definitions and limited long-term safety data.very low to low quality evidence
Large multicenter RCTs comparing G-POEM to sham or alternative treatments are needed.
Stretta (radiofrequency) for GERD: Evidence for Stretta is mixed: some observational series report symptom and quality-of-life improvements, but randomized and controlled data are inconsistent and overall evidence quality is low and inconclusive compared with surgical fundoplication.
Conditional coverage considerations for endoscopic/transoral GERD procedures
Consider coverage for endoscopic/transoral GERD procedures when ALL of the following context factors documented:
Selection and evidence context: Patient has chronic GERD symptoms despite optimized medical therapy (including PPI), with documented objective evidence of pathologic reflux or anatomic contributors (e.g., abnormal pH/DeMeester, endoscopic findings, hiatal hernia size consistent with trial inclusion).documented objective testing (pH monitoring, endoscopy)
Procedure-specific evidence and alignment: The selected device/procedure has peer-reviewed evidence and the patient matches populations studied in RCTs or prospective cohorts (for example, hiatal hernia ≤2–3 cm in many TIF/MSA trials).device-specific inclusion criteria documented
Document the device indication and comparison to published inclusion criteria.
Informed consent and counseling:
Coverage considerations / candidate selection
Clinical situations and study inclusion criteria commonly reported — useful when defining medical necessity:
Typical candidate criteria for TIF/MSA in studies: Chronic PPI use with persistent GERD symptoms; objective evidence of pathologic reflux (abnormal pH/DeMeester); limited hiatal hernia size (commonly ≤2–3 cm); absence of advanced esophagitis or Barrett's esophagus in many trial populations.trial-specific cutoffs (e.g., hiatal hernia ≤2–3 cm)
Trials varied in numeric cutoffs; document how patient meets the study-like criteria.
Reported beneficial outcomes: Outcomes reported in trials include symptom improvement (GERD-HRQL, RSI), reduction or cessation of daily PPI use, elimination of troublesome regurgitation, and improved quality of life; magnitude and durability vary by procedure and study.varies by study (e.g., ≥50% symptom score reduction)
Long-term durability varied; some studies report increasing PPI use over time.
Safety and limitations:
Evidence-informed coverage considerations
Clinical evidence and guideline conclusions relevant to coverage:
MSA as alternative to fundoplication: Society guidelines and systematic reviews conclude magnetic sphincter augmentation (MSA/LINX) can be an effective option and may be considered as an alternative to laparoscopic fundoplication for patients with regurgitation who fail medical management; randomized data show superior regurgitation control versus double-dose PPI at 6 months.
References include Bell et al. RCT, ACG guidance, and SAGES analyses.
MSA outcomes and safety signals: Reported benefits include high rates of PPI withdrawal and symptom improvement; risks include transient and persistent dysphagia, need for dilation, device removal (~2.7% in large series), and rare erosion events.
Long-term comparative data beyond 1–3 years remain limited and warrant continued surveillance.
Gastroparesis device indication: Enterra gastric electrical stimulation (GES) is FDA-authorized under a Humanitarian Device Exemption (HDE) for chronic, intractable (drug-refractory) nausea and vomiting due to diabetic or idiopathic gastroparesis in adults; device labeling and contraindications should be followed.
Refractory gastroparesis interventions
Coverage rationale updates (summary of statements in this revision):
GES medical necessity: Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.failed other therapies
Statement added in 02/01/2026 revision; refer to FDA HDE information.
Surgical pyloroplasty medical necessity: Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.failed other therapies
Statement added in 02/01/2026 revision.
The policy designates endoluminal therapy with GERDx™ as investigational and not medically necessary for treatment of GERD because it has not received U.S. Food and Drug Administration approval and evidence of long‑term efficacy is insufficient. In the same category of unproven interventions for GERD, the policy lists a range of endoscopic therapies, injection or implantation techniques, and the LINX Reflux Management System as not medically necessary due to limited, low‑quality, or inconsistent evidence supporting sustained symptom control and objective reflux reduction.
The policy clarifies that procedures lacking evidence of benefit compared with less invasive alternatives — or performed without documentation of medically refractory disease and appropriate preprocedure evaluation — may be excluded from coverage. Examples cited include endoscopic plication/suturing and related techniques where studies often lacked randomization, controls, or adequate assessment of prior maximal medical therapy, and long‑term follow‑up showed loss of benefit and continued PPI use in many patients.
Procedures used outside of rigorously conducted study protocols or with inadequate long‑term safety and effectiveness data should be considered investigational. The policy highlights Z‑POEM, G‑POEM, Stretta, and other novel endoscopic approaches as examples where evidence is limited to small series, retrospective studies, or short follow‑up periods; the document states that higher‑quality prospective comparative trials with longer follow‑up are needed before routine coverage can be supported.
The policy emphasizes that procedures performed without objective evidence of GERD or without appropriate preprocedure evaluation may not be supported. Prior to considering device‑based or endoscopic antireflux procedures, documentation of pathologic reflux and objective testing (for example, ambulatory pH monitoring and upper endoscopy per trial inclusion criteria) and a history of optimized PPI therapy are repeatedly recommended to justify intervention.
Payers and clinicians should exercise caution for procedures where long‑term safety and efficacy data are insufficient. The policy cites Stretta (radiofrequency), injectable bulking agents (Plexiglas/Durasphere), and the LINX magnetic sphincter device as examples with unresolved uncertainties about durability, comparative effectiveness versus fundoplication, and long‑term device‑related complications; the guideline summaries and HTA reports referenced note the need for larger randomized trials and longer follow‑up.
The Enterra Therapy System labeling identifies specific contraindications that should be observed when considering gastric electrical stimulation. According to the FDA HDE labeling, Enterra is indicated for chronic, intractable (drug‑refractory) nausea and vomiting due to diabetic or idiopathic gastroparesis in adults 18–70, and it should not be used in patients with gastric obstruction or pseudo‑obstruction, prior gastric resection, prior fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting.
No additional explicit exclusions are listed in the cited policy revision text. The document does, however, reiterate that final coverage determinations are governed by the member‑specific benefit plan and that medical records may be required to confirm whether clinical criteria are met.
The policy lists several procedures as not medically necessary for routine coverage, including POEM for indications other than achalasia or diffuse esophageal spasm, G‑POEM for gastroparesis, and multiple endoscopic or implantable therapies for GERD (for example, endoscopic plication/suturing systems, injectable bulking agents, Stretta, and LINX when long‑term benefit is not established). The document states these techniques are unproven due to insufficient high‑quality comparative evidence and limited long‑term outcome data.
Gastric electrical stimulation (GES) performed solely based on open‑label series without adequate demonstration of medically refractory symptoms, objective baseline assessments, and longer‑term comparative data may be insufficient to justify coverage in some cases. The policy references controlled randomized crossover trials with mixed findings and notes that single‑center cohorts, while showing symptomatic response, have limitations (lack of control groups and unclear follow‑up) that can affect the strength of coverage decisions.
Because the overall quality of evidence for several of these techniques is low to very low and long‑term durability is uncertain, the policy concludes that many novel endoscopic and implantable methods should be considered not medically necessary for routine use until stronger comparative evidence with longer follow‑up is available. This includes G‑POEM for gastroparesis and a number of endoscopic antireflux procedures where randomized, sham‑controlled or head‑to‑head trials are lacking.
Multiple case series and randomized trials reported progressive loss of benefit over time and high rates of continued proton pump inhibitor use after some endoscopic therapies. The policy cites long‑term follow‑up data (for example, EndoCinch and other plication/suturing reports) that demonstrated symptom improvements at early time points but diminishing effects by 3–5 years and substantial proportions of patients remaining on PPI therapy.
Injectable bulking agents such as Plexiglas (PMMA) and Durasphere have been evaluated in small series and systematic reviews, but available evidence is insufficient to establish their effectiveness and long‑term safety for GERD. The policy indicates that randomized studies with adequate follow‑up are needed before these agents can be considered proven and routinely covered.
The policy notes external guidance (for example, NICE) that highlights uncertainty about longer‑term outcomes for some endoscopic procedures such as radiofrequency ablation (Stretta). While short‑ and medium‑term symptomatic relief is reported, objective evidence of sustained reflux control and long‑term durability remains inconclusive, supporting the policy’s cautious stance.
Language in this revision removed prior text that had characterized functional lumen imaging probe (FLIP) technology as unproven and not medically necessary for diagnosing achalasia. The policy update therefore no longer includes that negative designation for FLIP and reflects the documented change in the policy history.
Applicable Procedure and Device Codes
Applicable CPT Codes (part 1)CPT
43210
Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257
Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284
Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648
Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659
Unlisted laparoscopy procedure, stomach.
43881
Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
Applicable CPT Codes (part 2)CPT
43882
Revision or removal of gastric neurostimulator electrodes, antrum, open.
43999
Unlisted procedure, stomach.
64590
Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595
Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.
FDA device references and approvals (no explicit CPT/HCPCS codes listed in this section)mixed
No codes listed
Applicable CPT Codes addedCPT
43647
43648
43659
43881
43882
64590
64595
Prior Authorization, Documentation, and Billing Guidance
Prior Authorization
Prior Authorization Required for GES and Z-POEM
Prior authorization is required for gastric electrical stimulation (GES) and Z-POEM. For GES, prior authorization should confirm medically refractory gastroparesis (failed conservative and medical therapies), document that the device is being used consistent with FDA/HDE labeling (Enterra™ indications and contraindications), and include relevant medical records (symptom severity, prior treatments, gastric emptying testing). For Z-POEM, prior authorization should document diagnosis (Zenker's diverticulum), prior standard therapies attempted, and that the procedure is being requested despite limited long-term comparative evidence.
Confirm medically refractory gastroparesis for GES (failed lifestyle modification, maximal medical therapy).
For Z-POEM, document prior therapies attempted and provide rationale given limited long-term evidence.
Prior Authorization
Prior Authorization for Novel Endoscopic Foregut Procedures
Prior authorization is required for novel endoscopic foregut procedures (e.g., G-POEM, endoscopic fundoplication/TIF, Stretta, endoscopic plication/suturing, MUSE, LINX when applicable). Given limited or evolving evidence for many of these procedures, PA requests should include clear documentation of refractory symptoms, prior treatments tried, and objective testing where applicable.
Clinical Background and Scope
Gastroparesis is defined as delayed gastric emptying associated with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain; diagnosis requires objective evidence of delayed gastric emptying (for example, scintigraphic gastric emptying testing). The policy notes that GES and surgical pyloroplasty are indicated for refractory gastroparesis—that is, persistent symptomatic disease after failure of other therapies—and for chronic, intractable (drug‑refractory) nausea and vomiting of diabetic or idiopathic etiology.
Key Terms and Device Definitions
Achalasia — definition and key features
DefinitionA primary esophageal motor disorder characterized by degeneration of the myenteric plexus resulting in impaired relaxation of the esophagogastric junction and loss of organized peristalsis in the esophageal body.
Typical presentationDysphagia, regurgitation, and chest pain due to failure of lower esophageal sphincter relaxation and absent peristalsis.
Diagnostic approachConfirmed by esophageal manometry demonstrating impaired EGJ relaxation and absent/abnormal peristalsis.
Relevance to policyPOEM is considered a proven and medically necessary treatment option for achalasia when diagnostic testing confirms the disorder.
Diffuse Esophageal Spasm — definition
Definition
Policy Summary
Payersierra health and life
PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases
Policy CodePolicy 2026T0322LL
Change TypeMaterial revisions to gastroparesis and pyloroplasty coveragecode additions
Effective DateFeb 1, 2026
Next Review Date
Key ActionObtain prior authorization documenting medically refractory gastroparesis and prior therapy failure before scheduling GES or surgical pyloroplasty.
POEM is supported for achalasia by randomized and comparative data demonstrating efficacy and noninferiority to LHM; document indication, prior treatments, informed consent, and counseling on reflux risk post-POEM.
diagnosis confirmed by manometry and appropriate candidate selection
Werner RCT demonstrates noninferiority at 2 years but higher reflux rates with POEM.
Z-POEM for Zenker's diverticulum (select centers): Z-POEM may be considered in expert centers for symptomatic Zenker's diverticulum when alternative therapies are unsuitable, but evidence is limited and long-term comparative data are insufficient.case-by-case justification and specialized expertise documented
Require specialist experience and individualized justification.
High-quality RCTs with long-term outcomes are required.
Patient was counseled about variable evidence quality, durability concerns, and procedure-specific risks (including reported severe adverse events for some devices), and consent is documented.
documented counseling and consent
Counseling should include comparative effectiveness versus fundoplication and possibility of continued PPI use.
Preference or unsuitability of alternatives: There is documentation that surgical fundoplication is unsuitable, refused, or the patient prefers a less-invasive transoral approach after informed counseling, or prior fundoplication contraindicates other options.clinical justification documented
Comparative evidence often favors fundoplication for objective reflux control.
Adverse events reported include transient or persistent dysphagia (noted with MSA), need for dilation or device removal, rare serious events for some devices, and heterogeneous long-term follow-up; these risks and limitations should be documented.
reported event rates vary
Device-specific safety signals (e.g., postoperative dysphagia, device removal) should be included in counseling and documentation.
FDA HDE indication and contraindications observed
Document device indication and applicable contraindications per labeling.
Document failure of conservative and medical therapy prior to consideration of endoscopic foregut procedures.
Provide prior treatment history (duration and response to PPIs, prokinetics, dietary measures, etc.).
Include device-specific indication and any FDA clearance/approval information when applicable.
Documentation Required
Prior Authorization: Objective Testing and PPI History
Prior authorization must require objective testing and a documented PPI history for GERD-related procedures. PA submissions should include objective evidence of disease (e.g., abnormal ambulatory pH testing/DeMeester score, endoscopy findings, manometry when indicated) and documentation of PPI use and response.
Document chronic GERD symptoms and duration.
Provide PPI history: trials, doses, duration, and response (including maximal medical therapy where applicable).
Attach objective testing results: ambulatory pH monitoring, endoscopy (esophagitis grade), esophageal manometry, and DeMeester score when available.
Prior Authorization
Prior Authorization Should Require Objective Testing and Prior Medical Therapy
Prior authorization for procedures such as TIF 2.0, LINX, MSA, and other device-based therapies should require objective abnormal testing and documented prior medical therapy (maximal PPI therapy). Studies and guidelines supporting these procedures generally enrolled chronic PPI users and/or required abnormal acid exposure; PA should reflect those trial entry criteria.
Require evidence of pathologic esophageal acid exposure or other objective criteria matching published trial eligibility when applicable.
Require documentation of maximal medical therapy (e.g., twice-daily PPI trials) and failure or intolerance.
If device is FDA-cleared/approved, include device labeling indication and any restrictions.
Prior Authorization
Prior Authorization: Document Device Indication and Prior Therapy
For FDA‑approved or cleared devices, prior authorization must document the device indication, label-concordant use, and prior therapy attempts. Include device-specific information (PMA/510(k)/HDE references) and clinical justification when requesting coverage.
Cite device approval/clearance (PMA/510(k)/HDE) and include device model when applicable (e.g., Enterra, EsophyX, MUSE, LINX, Stretta).
Provide documentation that member meets labeled indications and lacks labeled contraindications.
Document prior conservative and medical therapies attempted and outcomes.
Note
Verify Member Benefits and PA Requirements
Verify member benefits and any applicable prior authorization requirements before submitting requests. Inclusion of a CPT/diagnosis code in this policy does not guarantee coverage; member-specific plan documents govern final determinations.
Check member-specific benefit plan for PA requirements, exclusions, and any state or federal mandates.
Listing of a code in this policy is for reference only and does not guarantee reimbursement or coverage.
Denial Risk
Documentation Triggers for Denial
Lack of required medical records or objective documentation may trigger denial of authorization requests. Ensure complete submission of supporting clinical records, objective test results, symptom severity measures, and prior therapy documentation.
Missing documentation of prior medical therapy, objective testing, or symptom severity may lead to denial.
Provide validated symptom scores (e.g., GCSI, GERD‑HRQL) when available and relevant.
Denial Risk
Evidence Limitations May Affect Authorization
Evidence limitations for many novel endoscopic foregut and gastroparesis procedures may affect authorization decisions. Insufficient high-quality, long-term, comparative data or small case series with short follow-up increase uncertainty and may prompt requests for additional documentation or denial.
Procedures lacking RCTs with long-term follow-up or robust comparative evidence (e.g., some G-POEM, Z-POEM, endoscopic plication techniques) are at higher risk for non-coverage.
PA reviewers may require stronger justification, registry enrollment, or repeated documentation of failure of standard therapies.
Denial Risk
Insufficient Evidence May Trigger Denial
Insufficient or low‑quality evidence (small sample size, single‑center series, lack of control group, short follow-up) may trigger denial or the requirement for additional supporting information. When evidence is uncertain, document clinical benefit, alternatives tried, and risk/benefit rationale.
Provide comparative rationale when requesting procedures where evidence is limited (explain why alternative, better‑studied options are not appropriate).
If available, include enrollment in clinical trials or registries and longer-term follow-up data.
Denial Risk
Contraindications That May Trigger Denial
Clinical contraindications consistent with device labeling or safety concerns should be documented; presence of contraindications may result in denial. Examples include Enterra device contraindications and other device- or procedure-specific exclusions.
Common contraindications to consider: gastric obstruction/pseudo-obstruction, prior gastric resection or fundoplication, active eating disorder, uncontrolled seizure disorder, chemical dependency, or primary swallowing disorders.
If contraindications are present, provide clinical rationale if an exception is requested.
Step Therapy
Conservative Therapy and Step-Therapy Expectations
Conservative therapy and maximal medical management are expected before approving invasive interventions for gastroparesis and GERD. Step therapy principles apply: require failure of medical therapy (including appropriate PPI trials, prokinetics, dietary measures) prior to pyloric or device-based interventions.
Document duration and adequacy of medical therapy trials and reasons for failure or intolerance.
Consider pyloric interventions (pyloroplasty, G-POEM) after failure of recommended medical and conservative measures; in some cases pyloric interventions may be considered earlier based on clinical judgment and documentation.
A rare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions of normal amplitude accompanied by dysphagia.
Clinical featuresIntermittent chest pain, dysphagia for solids and liquids, and possible weight loss.
DiagnosisEstablished with esophageal manometry showing spastic, simultaneous contractions rather than organized peristalsis.
DefinitionA condition in which the lower esophageal sphincter relaxes too often or weakens, allowing stomach acid to reflux into the esophagus.
Common consequencesHeartburn, regurgitation, esophagitis, strictures, and risk of Barrett's esophagus with chronic uncontrolled reflux.
Diagnostic testsObjective testing can include endoscopy and ambulatory pH monitoring to document pathologic acid exposure.
Gastroparesis — definition and diagnostic criteria reference
DefinitionGastroparesis is a disorder of delayed gastric emptying due to abnormal or absent stomach motility (aka delayed gastric emptying).
Diagnostic criteriaDiagnosis requires objective evidence of delayed gastric emptying, commonly by scintigraphic gastric emptying testing.
Clinical manifestationsNausea, vomiting, early satiety, postprandial fullness, bloating, and possible weight loss.
Humanitarian Use Device (HUD) — HUD designation and relevance to GES
HUD designationA Humanitarian Use Device (HUD) is an FDA designation permitting use of devices for conditions affecting small populations where evidence is limited.
GES relevanceThe ACG notes GES may be considered as a HUD for medically refractory diabetic or idiopathic gastroparesis, aligning Enterra's HDE marketing status.
Policy implicationHUD status supports case-by-case consideration for GES in refractory gastroparesis but requires documentation of failed standard therapies.
Eckardt score definitionA validated symptom score used in achalasia trials; clinical success commonly defined as an Eckardt score of 3 or less at follow-up.
Use in trialsUsed as primary outcome in trials comparing POEM to laparoscopic Heller myotomy (Werner RCT used Eckardt ≤3 at 2 years).
DocumentationBaseline and follow-up Eckardt scores are recommended to document symptom severity and treatment response.
Z-POEM / G-POEM — definitions and intended effects
DefinitionZ-POEM and G-POEM are peroral endoscopic myotomy techniques applying endoscopic myotomy to Zenker's diverticulum (Z-POEM) or the gastric pylorus (G-POEM) to relieve outflow obstruction.
Intended effectZ-POEM aims to treat symptomatic Zenker's diverticulum; G-POEM aims to improve gastric emptying and reduce gastroparesis symptoms by myotomy of the pyloric sphincter.
Evidence contextEvidence for Z-POEM and G-POEM is limited with heterogeneous definitions of success and insufficient long-term comparative data; G-POEM overall evidence quality rated very low to low.
Stretta — definition of radiofrequency treatment
DefinitionStretta is an endoscopic system delivering radiofrequency thermal energy to the gastroesophageal junction intended to reduce GEJ compliance and improve GERD symptoms.
MechanismRadiofrequency lesions produce submucosal scarring and tissue shrinkage around the LES to reduce reflux.
Evidence summaryEvidence is mixed: some case series report durable symptom improvement up to 10 years, but RCTs and systematic assessments rate overall evidence as low quality and inconclusive versus fundoplication.
EFTP / endoscopic full-thickness fundoplication — definition and trial context
DefinitionEndoscopic full-thickness fundoplication (EFTP) is an endoscopic plication/suturing technique that creates a full-thickness fundoplication via a transoral approach to reduce reflux.
Trial contextA randomized, double-blind sham-controlled trial (Kalapala et al. 2022) showed 65.7% of EFTP patients achieved ≥50% reduction in GERD-HRQL vs 2.9% with sham; larger trials with longer follow-up are needed.
Practical noteProcedure selection should align with device-specific inclusion criteria and objective reflux testing used in trials.
MechanismStretta delivers radiofrequency energy to the gastroesophageal junction to produce thermal lesions and submucosal scarring intended to tighten the LES region.
Clinical findingsSome observational series and systematic reviews report symptom and quality-of-life improvements, but randomized and comparative studies provide low-quality evidence and show uncertain comparative effectiveness versus fundoplication.
Evidence gapsHigh-quality RCTs with long-term patient-centered outcomes comparing Stretta to other procedures or sham are needed.
Device-based definitionTransoral Incisionless Fundoplication (TIF) using the EsophyX system is a device-based transoral fundoplication intended to reconstruct the gastroesophageal valve at the GEJ without external incisions.
Intended outcomesDesigned to control GERD symptoms, reduce PPI dependence, and improve quality of life with long-term durability reported in some series up to 5-10 years.
Evidence summarySystematic reviews and RCTs report symptom improvement and PPI reduction in selected patients, but overall evidence quality is variable and long-term comparative data are limited.
Procedure contextTransoral Incisionless Fundoplication (TIF) refers to endoscopic fundoplication performed with the EsophyX device (TIF 2.0 referenced) to reconstruct the gastroesophageal valve.
Patient selectionTrials commonly enrolled chronic PPI users with abnormal pH and limited hiatal hernia size; exclusion of advanced esophagitis or Barrett's in some studies was common.
Outcomes and limitationsReported benefits include symptom improvement and reduced PPI use; limitations include small trial sizes, crossover designs, and loss to long-term follow-up in several studies.
MSA (Magnetic Sphincter Augmentation) / LINX — device definition and function
Device descriptionMagnetic Sphincter Augmentation (MSA) with the LINX Reflux Management System is a laparoscopically implanted ring of magnetic beads placed around the lower esophageal sphincter to augment closure and reduce reflux.
Regulatory statusLINX received FDA premarket approval (PMA P100049) for the device; multiple PMA supplements exist.
Clinical profileStudies report high rates of PPI discontinuation and symptom improvement, but risks include postoperative dysphagia, need for dilation, and device removal in a minority of patients; long-term comparative data remain limited.
Injectable bulking agents — definition and evidence limitation
DefinitionInjectable bulking agents are materials (e.g., Durasphere, Plexiglas) injected endoscopically into the gastroesophageal junction to bulk the LES region and reduce reflux.
Evidence limitationAvailable evidence is limited to small case series and systematic reviews that conclude evidence is insufficient to establish long-term safety and effectiveness for GERD treatment.
Regulatory noteSome agents are approved for other indications (e.g., Durasphere for urology), and use for GERD would be off-label; randomized trials are needed.
Enterra Therapy System — HUD device definition and indication
Device identityThe Enterra Therapy System is a gastric electrical stimulation device marketed under an FDA Humanitarian Device Exemption (HDE) for chronic, intractable (drug-refractory) nausea and vomiting due to diabetic or idiopathic gastroparesis in adults 18–70 years.
Indication specificsHDE approval specifies use for chronic intractable nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology; contraindications include gastric obstruction, prior gastric resection or fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, and psychogenic vomiting.
Clinical guidanceACG guidance notes GES may be considered as a HUD for medically refractory gastroparesis; policy relocation clarifies GES proven and medically necessary for refractory gastroparesis in this revision.
LINX Reflux Management System — PMA device definition and identifier
Device identityThe LINX Reflux Management System is a magnetic sphincter augmentation device implanted laparoscopically to augment the lower esophageal sphincter for GERD management.
Clinical considerationsReported benefits include high rates of PPI discontinuation and symptom control; long-term safety and comparative effectiveness data are limited and under active study.
Injectable bulking agents — definition and evidence limitation (repeat)
DefinitionInjectable bulking agents (e.g., Plexiglas, Durasphere) are injected into the gastroesophageal junction to increase bulk and reduce reflux.
Evidence limitationSystematic reviews and small studies report mixed outcomes; overall evidence is insufficient to consider these agents proven and safe for GERD treatment.
Regulatory noteSome agents are approved for non-esophageal indications; use for GERD is off-label and additional randomized studies are warranted.